Table 5 Ricarte Soto Law – Covered Rare Diseases [37]
From: A civil society view of rare disease public policy in six Latin American countries
Disease/Condition | Treatment | |
|---|---|---|
Current Coverage | ||
1 | Mucopolysaccharidosis I | Laronidase |
2 | Mucopolysaccharidosis II | Idursulfase |
3 | Mucopolysaccharidosis VI | Galsulfase |
4 | Tyrosinemia | Nitisinone |
5 | Gaucher Disease | Taliglucerase or Imiglucerase |
6 | Fabry Disease | Agalsidase Alfa or Beta |
7 | Pulmonary Arterial Hypertension (Group 1) | Ambrisentan, Bosentan, or Iloprost |
8 | Hereditary Angioedema | C1 Esterase Inhibitor |
Additions for Coverage beginning July 1, 2019 | ||
9 | Epidermolysis Bullosa (dystrophic or junctional) | Treatment Pack |
10 | Amyotrophic Lateral Sclerosis (moderate to severe) | Technical Assistance and Devices |
11 | Gastrointenstinal Stromal Tumor (GIST) | Imatinib or Sunitinib |
12 | Psoriatic Arthritis (moderate to severe, refractory) | Golimumab, Etanercept, Adalimumab, or Secukinumab |
13 | Ulcerative Colitis (moderate to severe, refractory) | Golimumab or Adalimumab for moderate; Infliximab for severe |
14 | Myelofibrosis (primary and secondary to other myeloproliferative neoplasms) | Ruxolitinib |
15 | Huntington’s Disease (chorea) | Tetrabenazina |